Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Roche has received the European Commission (EC) approval for the use of MabThera (rituximab) as a maintenance treatment for people suffering from follicular lymphoma who have responded to initial induction therapy.
Subscribe to our email newsletter
According to Roche, the EC approval is based on the results from the phase III Prima study which demonstrated that continuing MabThera for two years (maintenance treatment) in patients who responded to initial treatment with MabThera plus chemotherapy doubled the likelihood of these patients living without their disease worsening, compared to those who did not receive maintenance therapy.
Prima trial principal investigator Gilles Salles said that the approval of MabThera maintenance therapy in the EU is a significant step that will change the way we manage this chronic disease.
"Having access to this new treatment option will enable patients with this serious form of blood cancer to live their lives with their disease under better control," Salles said.